RS62034B1 - Kompozicije za lečenje raka - Google Patents

Kompozicije za lečenje raka

Info

Publication number
RS62034B1
RS62034B1 RS20210531A RSP20210531A RS62034B1 RS 62034 B1 RS62034 B1 RS 62034B1 RS 20210531 A RS20210531 A RS 20210531A RS P20210531 A RSP20210531 A RS P20210531A RS 62034 B1 RS62034 B1 RS 62034B1
Authority
RS
Serbia
Prior art keywords
cancer
day
hydroxylase
abiraterone acetate
compositions
Prior art date
Application number
RS20210531A
Other languages
English (en)
Serbian (sr)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62034(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of RS62034B1 publication Critical patent/RS62034B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20210531A 2006-08-25 2007-08-23 Kompozicije za lečenje raka RS62034B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
EP12160586.9A EP2478907B1 (en) 2006-08-25 2007-08-23 Compositions for treating cancer

Publications (1)

Publication Number Publication Date
RS62034B1 true RS62034B1 (sr) 2021-07-30

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20210531A RS62034B1 (sr) 2006-08-25 2007-08-23 Kompozicije za lečenje raka
RS20130401A RS52956B (sr) 2006-08-25 2007-08-23 Kompozicije za tretman kancera

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20130401A RS52956B (sr) 2006-08-25 2007-08-23 Kompozicije za tretman kancera

Country Status (20)

Country Link
EP (3) EP2478907B1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20090059126A (enExample)
CN (2) CN104306977A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2478907T3 (enExample)
ES (2) ES2428634T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2061561T3 (enExample)
PT (2) PT2061561E (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2061561T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100261689A1 (en) * 2007-10-29 2010-10-14 Masuo Yamaoka Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
BR112013017722A2 (pt) 2011-01-11 2016-07-12 Glaxosmithkline Llc combinação
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
WO2014052237A1 (en) 2012-09-26 2014-04-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
EP2983639A1 (en) * 2013-04-04 2016-02-17 Exelixis, Inc. Drug combinations to treat cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
MX2016004267A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CA2923899A1 (en) * 2013-10-01 2015-04-09 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3824908A1 (en) * 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
CA2401304A1 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1583539A2 (en) * 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka

Also Published As

Publication number Publication date
HRP20130961T1 (hr) 2013-11-22
EP2478907A2 (en) 2012-07-25
KR20150108946A (ko) 2015-09-30
JP2019059750A (ja) 2019-04-18
JP2020114851A (ja) 2020-07-30
AU2007287098C1 (en) 2018-03-15
EP2478907A3 (en) 2012-08-01
HRP20210670T1 (hr) 2021-06-11
HK1131577A1 (en) 2010-01-29
EP2478907B1 (en) 2021-04-14
AU2007287098A1 (en) 2008-02-28
AU2015221447B9 (en) 2017-07-20
CN104306977A (zh) 2015-01-28
WO2008024484A1 (en) 2008-02-28
IL257681A (en) 2018-04-30
EP2061561A1 (en) 2009-05-27
CA2661422C (en) 2017-06-27
AU2015221447B2 (en) 2016-12-15
IL227746A0 (en) 2013-09-30
JP6053279B2 (ja) 2016-12-27
PL2478907T3 (pl) 2021-10-25
JP6740497B2 (ja) 2020-08-12
CY1115477T1 (el) 2017-01-04
JP2022185091A (ja) 2022-12-13
NZ597830A (en) 2013-02-22
AU2007287098B2 (en) 2013-08-15
CA2661422A1 (en) 2008-02-28
DK2061561T3 (da) 2013-10-07
AU2018271331A1 (en) 2018-12-20
KR20090059126A (ko) 2009-06-10
PL2061561T3 (pl) 2013-12-31
PT2061561E (pt) 2013-10-09
CY1124221T1 (el) 2022-05-27
JP2017052791A (ja) 2017-03-16
AU2015221447A1 (en) 2015-09-17
JP2010501575A (ja) 2010-01-21
PT2478907T (pt) 2021-05-26
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
AU2017201764A1 (en) 2017-04-06
NO20200775A1 (no) 2009-03-20
JP6445123B2 (ja) 2018-12-26
ES2869343T3 (es) 2021-10-25
ES2428634T3 (es) 2013-11-08
CN101528308A (zh) 2009-09-09
SI2478907T1 (sl) 2021-08-31
JP2018065859A (ja) 2018-04-26
IL197211A0 (en) 2009-12-24
JP2015110577A (ja) 2015-06-18
DK2478907T3 (da) 2021-05-25
KR20200125776A (ko) 2020-11-04
AU2022206696A1 (en) 2022-08-11
SI2061561T1 (sl) 2013-11-29
HUE054495T2 (hu) 2021-09-28
JP2021038252A (ja) 2021-03-11
LT2478907T (lt) 2021-06-25
NO20091190L (no) 2009-03-20
EP3804730A1 (en) 2021-04-14
KR20180003636A (ko) 2018-01-09
JP2024164147A (ja) 2024-11-26
RS52956B (sr) 2014-02-28
JP2012082215A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
EP2061561B1 (en) Compositions for treating cancer
Chen et al. The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis
CN101624414B (zh) 一种抑制血管新生的硝酸酯药物
CN101669941B (zh) 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
EA032646B1 (ru) Режимы дозирования антипрогестинов
CN105873576A (zh) 治疗肥胖
EP3638233A1 (en) Tinostamustine for use in treating ovarian cancer
WO2018229130A1 (en) Compounds for treating tnbc
CN111386113A (zh) 包含lsz102和阿培利司的药物组合
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
JP2019513828A (ja) 改善された薬物動態を有するイソフラボノイド組成物
Girod et al. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets
JP2006513223A (ja) ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害
HK1131577B (en) Compositions for treating cancer
ES2310182T3 (es) 7-hidroxiepiandrosterona con actividad neuroprotectora.
HK1173966B (en) Compositions for treating cancer
CN114569545B (zh) 一种稳定的米托蒽醌制剂
CN107007611A (zh) 醋酸诺美孕酮在制备治疗子宫内膜癌的药物中的应用
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
Landström et al. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma
US20230364053A1 (en) Pharmaceutical composition for treatment of prostate cancer or breast cancer
WO2023093837A1 (zh) 含有铂类药物或者铂类药物共晶的药物组合物及其用途
WO2023172909A1 (en) Compositions comprising anti-progestins and selective estrogen receptor modulators and methods of using the same
US20220354815A1 (en) Okn-007 as a therapeutic agent
HK40101825A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib